Eupraxia Pharmaceuticals Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.32 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $7.83Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $517.4M Shares Outstanding 66.1M diluted Moat Rating None Next Earnings Date3 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Eupraxia Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ micro-sphere technology to deliver targeted, extended-release therapeutics. The company's lead candidate, EP-104GI, has demonstrated highly encouraging safety and efficacy data in its Phase 1b/2a RESOLVE trial for Eosinophilic Esophagitis (EoE), showing robust and durable responses up to 36 weeks without serious adverse events or candidiasis. Backed by a strong cash position of approximately $138.9 million following a successful $63.2 million public offering, Eupraxia is well-capitalized into the second half of 2028. This runway fully covers key upcoming clinical catalysts, including the Phase 2b RESOLVE top-line data expected in Q3 2026. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$11.00 Mean target$16.35 High · most bullish analyst$25.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The Phase 2b RESOLVE trial fails to replicate the positive efficacy trends of the open-label cohorts, or safety concerns emerge at higher doses. Additionally, escalating trade tensions and tariffs between the U.S. and Canada significantly inflate the cost of clinical supplies, accelerating cash burn and shortening the operational runway. Base CaseCentral scenario The Phase 2b portion of the RESOLVE trial for EP-104GI in EoE meets its primary endpoints, confirming the efficacy of the 120mg and 160mg doses. The company successfully initiates further clinical trials in additional market-expanding GI indications. The cash runway remains sufficient to support operations into H2 2028, and the stock moves toward the consensus analyst target. Bull CaseUpside scenario The bull case centers on the clinical and commercial success of Eupraxia's lead candidate, EP-104IAR, for knee osteoarthritis, and EP-104GI for Eosinophilic Esophagitis (EoE). Leveraging its proprietary Diffusphere sustained-release technology, EP-104 offers a single injection lasting 6+ months compared to the current 3-month standard of care. Successful Phase 3 trials and subsequent FDA approval would unlock a multi-billion dollar market, potentially driving peak sales to $900 million or more and de-risking the platform for label expansion to other joints and indications. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |